Clinical Trials Logo

Immune Checkpoint Inhibitor clinical trials

View clinical trials related to Immune Checkpoint Inhibitor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06074029 Active, not recruiting - Clinical trials for Biliary Tract Cancer

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Start date: December 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

1. Establish a predictive model for the efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with biliary tract cancers. By analyzing the dynamic changes of circulating tumor DNA (ctDNA) and other clinical and pathological features before and after ICI treatment in a cohort of patients with biliary tract tumors, a predictive model can be established to evaluate the efficacy of ICI treatment in the early stages or even before treatment, serving as a reliable tool for selecting patients who are likely to benefit from ICI treatment. 2. Investigate the clinical features of populations that benefit from different immune combination therapies. By comparing the differences and enrichment of mutations between patients receiving different treatment regimens, and if patients have sufficient pre-treatment tissue, further comparisons of differentially expressed genes and pathways may be made.

NCT ID: NCT05383716 Active, not recruiting - Clinical trials for Non Small Cell Lung Cancer

Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

NeoP
Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year